Cargando…

The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma

BACKGROUND: It has been suggested that lactate metabolism (LM) is crucial for the development of cancer. Using integrated single-cell RNA sequencing (scRNA-seq) analysis, we built predictive models based on LM-related genes (LMRGs) to propose novel targets for the treatment of LUAD patients. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Pengpeng, Pei, Shengbin, Gong, Zeitian, Ren, Qianhe, Xie, Jiaheng, Liu, Hong, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073691/
https://www.ncbi.nlm.nih.gov/pubmed/37033259
http://dx.doi.org/10.3389/fendo.2023.1154410
_version_ 1785019624778104832
author Zhang, Pengpeng
Pei, Shengbin
Gong, Zeitian
Ren, Qianhe
Xie, Jiaheng
Liu, Hong
Wang, Wei
author_facet Zhang, Pengpeng
Pei, Shengbin
Gong, Zeitian
Ren, Qianhe
Xie, Jiaheng
Liu, Hong
Wang, Wei
author_sort Zhang, Pengpeng
collection PubMed
description BACKGROUND: It has been suggested that lactate metabolism (LM) is crucial for the development of cancer. Using integrated single-cell RNA sequencing (scRNA-seq) analysis, we built predictive models based on LM-related genes (LMRGs) to propose novel targets for the treatment of LUAD patients. METHODS: The most significant genes for LM were identified through the use of the AUCell algorithm and correlation analysis in conjunction with scRNA-seq analysis. To build risk models with superior predictive performance, cox- and lasso-regression were utilized, and these models were validated on multiple external independent datasets. We then explored the differences in the tumor microenvironment (TME), immunotherapy, mutation landscape, and enriched pathways between different risk groups. Finally, cell experiments were conducted to verify the impact of AHSA1 in LUAD. RESULTS: A total of 590 genes that regulate LM were identified for subsequent analysis. Using cox- and lasso-regression, we constructed a 5-gene signature that can predict the prognosis of patients with LUAD. Notably, we observed differences in TME, immune cell infiltration levels, immune checkpoint levels, and mutation landscapes between different risk groups, which could have important implications for the clinical treatment of LUAD patients. CONCLUSION: Based on LMRGs, we constructed a prognostic model that can predict the efficacy of immunotherapy and provide a new direction for treating LUAD.
format Online
Article
Text
id pubmed-10073691
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100736912023-04-06 The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma Zhang, Pengpeng Pei, Shengbin Gong, Zeitian Ren, Qianhe Xie, Jiaheng Liu, Hong Wang, Wei Front Endocrinol (Lausanne) Endocrinology BACKGROUND: It has been suggested that lactate metabolism (LM) is crucial for the development of cancer. Using integrated single-cell RNA sequencing (scRNA-seq) analysis, we built predictive models based on LM-related genes (LMRGs) to propose novel targets for the treatment of LUAD patients. METHODS: The most significant genes for LM were identified through the use of the AUCell algorithm and correlation analysis in conjunction with scRNA-seq analysis. To build risk models with superior predictive performance, cox- and lasso-regression were utilized, and these models were validated on multiple external independent datasets. We then explored the differences in the tumor microenvironment (TME), immunotherapy, mutation landscape, and enriched pathways between different risk groups. Finally, cell experiments were conducted to verify the impact of AHSA1 in LUAD. RESULTS: A total of 590 genes that regulate LM were identified for subsequent analysis. Using cox- and lasso-regression, we constructed a 5-gene signature that can predict the prognosis of patients with LUAD. Notably, we observed differences in TME, immune cell infiltration levels, immune checkpoint levels, and mutation landscapes between different risk groups, which could have important implications for the clinical treatment of LUAD patients. CONCLUSION: Based on LMRGs, we constructed a prognostic model that can predict the efficacy of immunotherapy and provide a new direction for treating LUAD. Frontiers Media S.A. 2023-03-22 /pmc/articles/PMC10073691/ /pubmed/37033259 http://dx.doi.org/10.3389/fendo.2023.1154410 Text en Copyright © 2023 Zhang, Pei, Gong, Ren, Xie, Liu and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Zhang, Pengpeng
Pei, Shengbin
Gong, Zeitian
Ren, Qianhe
Xie, Jiaheng
Liu, Hong
Wang, Wei
The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma
title The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma
title_full The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma
title_fullStr The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma
title_full_unstemmed The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma
title_short The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma
title_sort integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073691/
https://www.ncbi.nlm.nih.gov/pubmed/37033259
http://dx.doi.org/10.3389/fendo.2023.1154410
work_keys_str_mv AT zhangpengpeng theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT peishengbin theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT gongzeitian theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT renqianhe theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT xiejiaheng theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT liuhong theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT wangwei theintegratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT zhangpengpeng integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT peishengbin integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT gongzeitian integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT renqianhe integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT xiejiaheng integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT liuhong integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma
AT wangwei integratedsinglecellanalysisdevelopedalactatemetabolismdrivensignaturetoimproveoutcomesandimmunotherapyinlungadenocarcinoma